The life sciences industry isn’t going to give up its biotech patents without a fight.
Powerful trade associations are warning that a decision last month from the U.S. Court of Appeals for the Federal Circuit that invalidated the patent on a prenatal blood test is threatening investment in biotechnology. Influential academics are urging the court to take Ariosa Diagnostics v. Sequenom en banc and set meaningful boundaries on the Supreme Court’s recent patent eligibility jurisprudence.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
